NASDAQ$ATEC
Alphatec Holdings Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Alphatec Holdings, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, highlighting significant revenue growth and progress in its strategic initiatives.
Alphatec Holdings, Inc. achieved a total revenue of $177 million in Q4 2024, demonstrating strong growth in surgical revenue by 28%. The company also reported a GAAP net loss of $33 million and generated $9 million in free cash flow, positioning itself for self-funded growth in the coming years.
- Total revenue for Q4 2024 reached $177 million.
- Surgical revenue grew by 28% in Q4 2024, driven by 19% surgical volume growth and a 7% increase in average revenue per surgery.
- The company increased new surgeon users by 20% during the quarter.
- Alphatec successfully entered the Japan market with its first surgery and generated $9 million of free cash flow in Q4 2024.
Headline financials
Revenue & EPS history
Alphatec · Revenue · Quarterly
$177M
Revenue by segment
Alphatec · $104M total across 1 segment · Q3 2023
- Surgical Revenue$104M—100.0%
Forward guidance
For the full year 2025, Alphatec Holdings, Inc. expects total revenue to approximate $732 million, representing approximately 20% growth compared to full year 2024. This includes surgical revenue of approximately $657 million and EOS revenue of approximately $75 million. The company also anticipates adjusted EBITDA of approximately $75 million, contributing to positive free cash flow.
Tailwinds
- Expected total revenue growth of approximately 20% for FY 2025.
- Anticipated surgical revenue of approximately $657 million for FY 2025.
- Expected EOS revenue of approximately $75 million for FY 2025.
- Anticipated adjusted EBITDA of approximately $75 million for FY 2025.
- Expected positive free cash flow for FY 2025.
Headwinds
- Uncertainty of success in developing new products or products currently in the pipeline.
- Uncertainties in the Company's ability to execute upon its strategic operating plan.
- Uncertainties regarding the ability to successfully license or acquire new products and their commercial success.
- Failure to achieve acceptance of the Company's products by the surgeon community.
- Failure to obtain FDA or other regulatory clearance or approval, or unexpected or prolonged delays in the process.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-1.5%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-0.1%
Avg return
30 days after
45%
29 / 64 earnings
Positive
+44.8%
Q3 2024
Best reaction
-43.2%
Q2 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | -27.1% | -23.3% | |
| Q4 2025 | +0.5% | -3.3% | -21.5% | |
| Q3 2025 | -0.8% | +17.8% | +36.7% | |
| Q1 2025 | +2.4% | +2.2% | +2.2% | |
| Q4 2024 | +9.6% | +6.1% | -7.9% | |
| Q3 2024 | +44.8% | +54.2% | +93.4% | |
| Q2 2024 | -32.8% | -33.7% | -30.2% | |
| Q1 2024 | -20.2% | -13.3% | -22.7% | |
| Q4 2023 | -7.4% | -11.1% | -8.6% | |
| Q3 2023 | +4.7% | -1.5% | +20.8% | |
| Q2 2023 | -7.1% | -10.4% | -5.2% | |
| Q1 2023 | +3.1% | +3.8% | +4.5% | |
| Q4 2022 | +1.6% | +7.9% | +6.3% | |
| Q3 2022 | -1.5% | -1.4% | +9.5% | |
| Q2 2022 | -0.2% | -3.8% | -10.9% | |
| Q1 2022 | -16.1% | -27.7% | -34.0% | |
| Q4 2021 | +3.1% | +3.4% | +4.4% | |
| Q3 2021 | -2.2% | -8.2% | -18.7% | |
| Q2 2021 | +2.4% | -5.8% | -0.2% | |
| Q1 2021 | -2.0% | -9.1% | -8.3% | |
| Q4 2020 | -7.6% | +4.2% | -2.1% | |
| Q3 2020 | +9.4% | +4.7% | +22.1% | |
| Q2 2020 | +21.8% | +5.6% | +3.1% | |
| Q1 2020 | -8.0% | -13.9% | +5.7% | |
| Q4 2019 | -8.4% | -20.8% | -47.2% | |
| Q3 2019 | +15.2% | +16.1% | +18.1% | |
| Q2 2019 | +9.3% | +8.5% | +26.2% | |
| Q1 2019 | +5.4% | +15.8% | +8.8% | |
| Q4 2018 | +14.7% | +16.6% | +22.1% | |
| Q3 2018 | -1.7% | -5.6% | -13.5% | |
| Q2 2018 | +4.7% | +15.0% | +28.1% | |
| Q1 2018 | -2.0% | -0.9% | -1.1% | |
| Q4 2017 | +0.9% | -5.0% | +1.2% | |
| Q3 2017 | -0.8% | -0.6% | -30.5% | |
| Q2 2017 | +2.4% | +2.4% | +40.2% | |
| Q1 2017 | +1.9% | +0.0% | -4.8% | |
| Q4 2016 | -16.0% | -27.0% | -45.8% | |
| Q3 2016 | -15.8% | -8.0% | -12.8% | |
| Q2 2016 | +2.5% | +0.0% | -6.5% | |
| Q1 2016 | -11.8% | — | — | |
| Q4 2015 | -13.8% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | -42.6% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | +7.4% | — | — | |
| Q3 2014 | -0.7% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +2.3% | — | — | |
| Q4 2013 | +22.3% | — | — | |
| Q3 2013 | -0.5% | — | — | |
| Q2 2013 | -3.9% | — | — | |
| Q1 2013 | -3.2% | — | — | |
| Q4 2012 | +2.6% | — | — | |
| Q3 2012 | -1.8% | — | — | |
| Q2 2012 | -2.5% | — | — | |
| Q1 2012 | -7.4% | — | — | |
| Q4 2011 | -0.5% | — | — | |
| Q3 2011 | -5.6% | — | — | |
| Q2 2011 | -10.4% | — | — | |
| Q1 2011 | +3.7% | — | — | |
| Q4 2010 | +0.4% | — | — | |
| Q3 2010 | -9.6% | — | — | |
| Q2 2010 | -43.2% | — | — | |
| Q1 2010 | +6.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro